Vaxcell-Bio Therapeutics Co., Ltd. (KOSDAQ:323990)

South Korea flag South Korea · Delayed Price · Currency is KRW
4,825.00
-115.00 (-2.33%)
Jun 10, 2026, 3:30 PM KST
Market Cap112.22B -48.2%
Revenue (ttm)n/a +13,737.3%
Net Incomen/a
EPSn/a
Shares Out 23.26M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume77,092
Open5,100.00
Previous Close4,940.00
Day's Range4,700.00 - 5,190.00
52-Week Range4,700.00 - 11,520.00
Beta0.66
Analystsn/a
Price Targetn/a
Earnings Daten/a

About Sampath Bank

Vaxcell-Bio Therapeutics Co., Ltd. develops and anticancer immunotherapy products in South Korea. The company was founded in 2010 and is headquartered in Hwasun-eup, South Korea. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 323990
Full Company Profile

Financial Performance

In 2024, Vaxcell-Bio Therapeutics's revenue was 1.90 billion, an increase of 13737.28% compared to the previous year's 13.72 million. Losses were -10.62 billion, 3.40% more than in 2023.

Financial Statements